Washington, Feb 7 (NationPress) In a significant move aimed at enhancing transparency, two US senators from opposing political parties have proposed new legislation this week that mandates prescription drug labels to reveal the locations where medicines and their critical components are produced. This proposal is intended to shed light on a supply chain that heavily depends on international manufacturing.

Democratic Senator Kirsten Gillibrand and Republican Senator Rick Scott emphasized that this initiative would empower patients, pharmacists, and medical professionals by providing clear information about the origins of the medications they rely on daily.

The legislation, named the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act or the CLEAR LABELS Act, aims to introduce new country-of-origin disclosure requirements for prescription drug labels in the United States.

“Americans have the right to know where their prescription medications are made to make informed healthcare decisions,” Gillibrand stated. She further noted that the proposed legislation would facilitate access to manufacturing information and bolster accountability within the pharmaceutical supply chain.

Gillibrand also mentioned that this measure would enhance access to “safe, effective, lifesaving medications” by providing patients and healthcare providers with clear and trustworthy information.

Scott highlighted that families currently lack essential information regarding the origins of their medicines.

“As parents and grandparents, we strive to make informed and safe choices that ensure the well-being of our families,” Scott remarked. “Yet, families remain uninformed about the sources of their drugs.”

Scott pointed out that the United States relies heavily on foreign nations for drug manufacturing and active pharmaceutical ingredients (APIs), citing China and India as major production centers. He warned that the lack of transparency and oversight poses risks to patient safety.

“This flawed system keeps patients in the dark regarding the origins of their medications,” Scott stated. “Families deserve to be assured that the drugs they consume are safe, regulated, and properly labeled.”

A significant number of prescription medications available in the United States, including their APIs, are produced overseas. Current federal labeling regulations do not mandate public disclosure of the origins of these ingredients or finished products. Consequently, patients, pharmacists, and healthcare providers often lack insight into the provenance of their medications.

The CLEAR LABELS Act would require prescription drug labels to indicate the original manufacturers of both finished drugs and APIs. This information could be presented directly on the label or made accessible through a link, barcode, or QR code connected to a searchable electronic database.

The senators assert that the objective is to provide patients and regulators with clear, upfront information regarding the manufacturing locations of medicines. They argue that transparency is a crucial initial step toward identifying vulnerabilities in the drug supply chain and mitigating risks to the availability of safe and effective treatments.

This legislative effort builds upon previous bipartisan initiatives by Gillibrand and Scott, which include an investigative report and over a dozen inquiries directed at federal agencies and pharmaceutical industry leaders to gather information on the US's reliance on foreign-produced generic drugs.

If passed, this bill would amend the Federal Food, Drug, and Cosmetic Act to broaden labeling requirements and enhance disclosure throughout the prescription drug supply chain.